查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球脊髓刺激市場 - 2023-2030
市場調查報告書
商品編碼
1348006

全球脊髓刺激市場 - 2023-2030

Global Spinal Cord Stimulation Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

脊髓刺激 (SCS) 是一種相對較新的技術，當原因無法完全治療或損傷無法修復時，可以幫助控制慢性疼痛。脊髓刺激療法可以緩解症狀並改善日常功能。

脊髓刺激使用溫和的電流來刺激脊髓中的某些神經纖維。脊髓刺激有助於有針對性地緩解疼痛。它可以幫助治療軀幹和/或四肢的慢性頑固性疼痛，包括單側或雙側疼痛。脊髓刺激可以改善整體生活品質和睡眠，並減少對止痛藥的需求。

動力學

先進設備的推出數量增加預計將加速市場成長

先進的脊髓刺激器有助於為患有慢性疼痛的患者提供有效的治療，從而增加對設備的需求並推動市場成長。例如，2022 年1 月24 日，全球醫療保健技術領導者美敦力公司(Medtronic Plc) 推出了兩種高度先進的脊髓刺激設備：Intellis 可充電神經刺激器和Vanta 免充電神經刺激器，用於治療與糖尿病週邊神經病變(DPN) 相關的慢性疼痛。

此外，2022 年 10 月 12 日，Nevro Corp.（一家為治療慢性疼痛提供全面、改變生活的解決方案的全球醫療器材公司）開發了 Senza HFX iQ 脊髓刺激 (SCS) 系統。 Senza HFX iQ 是第一個也是唯一一個基於人工智慧、向病患學習的 SCS 系統。

脊髓損傷數量的增加以及慢性病患者擴大採用脊髓刺激器作為藥物的替代品，預計將推動市場成長。

治療過程的高成本預計將阻礙市場成長

治療的高成本可能會導致患者從脊髓刺激轉向其他低成本藥物和止痛藥，進而影響市場成長。根據華盛頓州勞工和工業部資助的一項研究，植入脊髓刺激系統的平均總醫療費用為每位患者 19,246 美元至 47,190 美元。

其他因素，例如與脊髓刺激和脊髓液滲漏相關的併發症，可能會阻礙市場的成長。因此，它影響了市場的成長。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按設備類型分類區隔
  • 按指示顯示區隔
  • 最終使用者區隔
  • 按地區分類區隔

第 4 章：動力學

  • 影響因素
    • 動力
      • 先進設備的發布數量增加
    • 限制
      • 治療費用高
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 俄烏戰爭影響分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按裝置類型

  • 可充電植入式脈衝產生器
  • 不可充電
  • 傳統植入式脈衝產生器
  • 射頻刺激器

第 8 章：依指示

  • 失敗背部症候群（FBS）
  • 退化性椎間盤疾病
  • 複雜區域疼痛綜合症（CRPS）
  • 手術後疼痛
  • 蜘蛛網膜炎
  • 其他

第 9 章：最終用戶

  • 醫院
  • 專科診所
  • 骨科中心
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Medtronic Plc
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Abbott Laboratories
  • Synapse Biomedical (SBI)
  • Boston Scientific Corporation
  • Curonix LLC,
  • Cirtec Medical
  • Nevro Corporation
  • Gimer Medical.
  • Beijing Pinchi Medical Equipment Co., Ltd.
  • Saluda Medical Pty Ltd.

第 13 章：附錄

簡介目錄
Product Code: MD2176

Overview

Spinal cord stimulation (SCS) is a relatively new technology that can help manage chronic pain when the cause cannot be treated completely or the injury cannot be repaired. Spinal cord stimulation therapy offers relief and improved daily functioning.

Spinal cord stimulation uses a mild electrical current to stimulate certain nerve fibers in the spinal cord. Spinal cord stimulation helps in targeted pain relief. It is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. Spinal cord stimulation can improve overall quality of life and sleep and reduce the need for pain medicines.

Dynamics

Increased number of launches of advanced devices is expected to accelerate the market growth

Advanced spinal cord stimulators help provide efficient treatment to patients suffering from chronic pain, thus, increasing the demand for the devices and driving the market growth. For instance, on January 24, 2022, Medtronic Plc, a global leader in healthcare technology, introduced two highly advanced spinal cord stimulating devices, Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for treating chronic pain associated with diabetic peripheral neuropathy (DPN).

Furthermore, on October 12, 2022, Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the treatment of chronic pain, developed the Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients.

The increase in the number of spinal cord injuries and the increase in the adoption of spinal cord stimulators by chronic disease patients as an alternative to medication are the additional factors that are expected to drive the market growth.

High cost of the treatment procedure is expected to hinder market growth

The high cost of the treatment can affect the market growth by allowing the patients to shift from spinal cord stimulation to other low-cost drugs and painkillers. According to a study funded by the Washington State Department of Labor and Industries, the average total medical costs of implanting a spinal cord stimulating system range from $19,246-$47,190 per patient.

Other factors, such as complications associated with spinal cord stimulation and leakage in the spinal fluid, can hamper the market growth. Thus, it affects the market growth.

Segment Analysis

The global spinal cord stimulation market is segmented based on device type, indication, end-user, and region.

Rechargeable implantable pulse generator segment holds a significant position in the market share

The increase in the number of approvals of rechargeable implantable pulse generators is expected to hold a significant position in the market growth. For instance, BIOTRONIK, on April 19, 2023, received U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.

Additionally, on December 19, 2022, Abbott received the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Thus, an increase in the number of product approvals is expected to hold the segment in the dominant position.

Geographical Penetration

North America holds the largest market share in the global spinal cord stimulation market

North America holds a dominant market share due to the increase in the number of FDA approvals. Launches and distribution of a large number of products help make the treatment available to a number of individuals.

For instance, on January 19, 2022, Nevro Corp., a global medical device company, received FDA approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System for treating Non-Surgical Refractory Back Pain (NSRBP).

Additionally, on May 16, 2023, Abbott received the U.S. Food and Drug Administration (FDA) approval for expanding its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. Thus, increasing the number of FDA approvals is expected to drive the region's market share.

Competitive Landscape

Medtronic Plc, Abbott Laboratories, Synapse Biomedical (SBI), Boston Scientific Corporation, Curonix LLC, Cirtec Medical, Nevro Corporation, Gimer Medical., Beijing Pinchi Medical Equipment Co., Ltd., and Saluda Medical Pty Ltd. are the leading companies with significant market share.

Key Developments

  • On August 25, 2023, Medtronic plc, a global leader in healthcare technology, received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS).

COVID-19 Impact Analysis

COVID-19 has impacted the spinal cord stimulation market moderately. The treatment procedures have been postponed, and the follow-ups after the treatment procedures have been delayed. The development and manufacturing of the devices has been halted. This created a negative impact on the growth of the market.

Market Segmentation

By Device Type

  • Rechargeable implantable pulse generator
  • Conventional implantable pulse generator
  • Non-rechargeable
  • Radiofrequency stimulator

By Indication

  • Failed Back Syndrome (FBS)
  • Degenerative Disk Disease
  • Complex regional pain syndrome (CRPS)
  • Post-surgical pain
  • Arachnoiditis
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Orthopedic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global spinal cord stimulation market segmentation based on device type, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of spinal cord stimulation market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global spinal cord stimulation market report would provide approximately 61 tables, 59 figures, and 183 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of launches of advanced devices
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of the treatment procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Rechargeable implantable pulse generator *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-rechargeable
  • 7.4. Conventional implantable pulse generator
  • 7.5. Radiofrequency stimulator

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Failed Back Syndrome (FBS) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Degenerative Disk Disease
  • 8.4. Complex regional pain syndrome (CRPS)
  • 8.5. Post-surgical pain
  • 8.6. Arachnoiditis
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Orthopedic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abbott Laboratories
  • 12.3. Synapse Biomedical (SBI)
  • 12.4. Boston Scientific Corporation
  • 12.5. Curonix LLC,
  • 12.6. Cirtec Medical
  • 12.7. Nevro Corporation
  • 12.8. Gimer Medical.
  • 12.9. Beijing Pinchi Medical Equipment Co., Ltd.
  • 12.10. Saluda Medical Pty Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us